<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02913794</url>
  </required_header>
  <id_info>
    <org_study_id>BR-FMS-OS-402</org_study_id>
    <nct_id>NCT02913794</nct_id>
  </id_info>
  <brief_title>Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control</brief_title>
  <acronym>FIMARO</acronym>
  <official_title>A Single-center Cross-sectional Study to Evaluate the Effectiveness of Antihypertensive Treatment Including Fimasartan and the Dyslipidemia Treatment Including Rosuvastatin and to Assess the Association Between the Two Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fimasartan and Rosuvastatin for hypertension and dyslipidemia control
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2016</start_date>
  <completion_date type="Anticipated">March 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Co-relation between blood pressure and dyslipidemia</measure>
    <time_frame>12 weeks</time_frame>
    <description>Check the blood pressure and dyslipidemia control rates, also check the correlation between these two disease</description>
  </primary_outcome>
  <enrollment type="Anticipated">1056</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Hyperlipidemias</condition>
  <eligibility>
    <study_pop>
      <textblock>
        1,056 patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypertension patients who are taking an anti-hypertensive agent, including Fimasartan
             at least 12 weeks or more.

          -  Dyslipidemia patients who are taking dyslipidemia drug, including Rosuvastatin at
             least 12 weeks or more

          -  Patients who has blood pressure and lipid levels (Total cholesterol, LDL-C, HDL-C,
             non-HDL-C, * TG) checks 2 weeks before registration

        Exclusion Criteria:

          -  Patients being hospitalized

          -  Patients who stop taking Fimasartan or Rosuvastatin within 12 weeks 14 or more
             consecutive days

          -  Patients who have more than 400mg/dl triglyceride(TG) at the registration time
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyung-Jin Jung</last_name>
    <role>Study Director</role>
    <affiliation>Boryung Pharmaceutical Co., Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Myung-Sook Hong</last_name>
    <email>mshong@boryung.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong-Hoon Choie</last_name>
      <email>cdhlyj@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2016</study_first_submitted>
  <study_first_submitted_qc>September 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2016</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

